Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
17 Feb 2022
17 Feb 2022
Historique:
received:
02
05
2021
accepted:
14
01
2022
entrez:
18
2
2022
pubmed:
19
2
2022
medline:
19
2
2022
Statut:
epublish
Résumé
Estrogen may have opposing effects on health, namely increasing the risk of breast cancer and improving bone health by increasing bone mineral density (BMD). The objective of this study was to compare dual-energy X-ray absorptiometry (DXA) BMD between women newly diagnosed with breast cancer and matched controls without breast cancer. Women newly diagnosed with breast cancer treated between April 2012 and October 2017 were prospectively enrolled. A control group was established of women with negative mammography or breast ultrasound, matched 1:1 by age, body mass index, parity, and the use of hormone replacement therapy. All those included had DXA BMD, and lab assessments at enrollment. Of 869 women with newly diagnosed breast cancer, 464 signed informed consent. Of the 344 who completed the study protocol, 284 were matched to controls. Overall, the mean age was 58 years. Compared to the control group, for the breast cancer group, the mean vitamin D level was lower (48.9 ± 19.0 vs. 53.8 ± 28.8 nmol/L, p = 0.022); and mean values were higher of total hip BMD (0.95 ± 0.14 vs. 0.92 ± 0.12 g/cm
Identifiants
pubmed: 35177701
doi: 10.1038/s41523-022-00388-z
pii: 10.1038/s41523-022-00388-z
pmc: PMC8854387
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Bone. 2003 Mar;32(3):211-6
pubmed: 12667548
Tumour Biol. 2013 Dec;34(6):3509-17
pubmed: 23807676
Eur J Cancer. 2010 Aug;46(12):2196-205
pubmed: 20456946
JAMA. 1996 Nov 6;276(17):1404-8
pubmed: 8892715
Cancer Causes Control. 2012 Jul;23(7):1149-62
pubmed: 22622862
Steroids. 2015 Jul;99(Pt A):49-55
pubmed: 25304359
J Womens Health (Larchmt). 2017 Feb;26(2):159-168
pubmed: 27710162
Ann Epidemiol. 2014 Mar;24(3):222-7
pubmed: 24360852
Breast Cancer Res Treat. 2011 Apr;126(3):679-86
pubmed: 20838879
Clin Nutr ESPEN. 2019 Apr;30:170-184
pubmed: 30904218
Maturitas. 2007 Mar 20;56(3):312-21
pubmed: 17049767
J Clin Epidemiol. 2001 Apr;54(4):417-22
pubmed: 11297892
Medicine (Baltimore). 2013 May;92(3):123-131
pubmed: 23625163
Endocrinol Metab Clin North Am. 2017 Dec;46(4):935-945
pubmed: 29080644
Osteoporos Int. 2006;17(8):1196-201
pubmed: 16699738
Maturitas. 2010 Apr;65(4):348-51
pubmed: 20079983
Climacteric. 2011 Jun;14(3):352-61
pubmed: 21413864
Cancer Causes Control. 2001 Apr;12(3):213-22
pubmed: 11405326
JAMA. 1999 Dec 8;282(22):2156-63
pubmed: 10591338
PLoS One. 2013 Aug 05;8(8):e70980
pubmed: 23940680
Cancer. 2008 Sep 1;113(5):907-15
pubmed: 18666209
Breast Cancer Res Treat. 2007 Apr;102(2):181-8
pubmed: 17028986
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Breast Cancer Res Treat. 2013 Feb;138(1):261-71
pubmed: 23381744
Maturitas. 2000 Jul 31;36(1):27-34
pubmed: 10989239
Am J Epidemiol. 2002 Feb 15;155(4):339-45
pubmed: 11836198
Osteoporos Int. 2005 Dec;16(12):1627-32
pubmed: 15782281
Osteoporos Int. 2008 Oct;19(10):1497-504
pubmed: 18373052
Eur J Epidemiol. 2004;19(8):785-92
pubmed: 15469036
J Natl Cancer Inst. 2001 Jun 20;93(12):930-6
pubmed: 11416114
Bone Rep. 2017 Sep 21;7:83-89
pubmed: 29018837
Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:32-8
pubmed: 16273366
N Engl J Med. 1997 Feb 27;336(9):611-7
pubmed: 9032046